Trial · NCT00842712
Adverse events1,631
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,631
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | RASH | Skin and subcutaneous tissue disorders | Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Gem | 3 | 3 | |
| other | RASH | Skin and subcutaneous tissue disorders | Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Vin | 3 | 3 | |
| other | RASH | Skin and subcutaneous tissue disorders | Safety run-in Part: Cil (2000 mg) + Cetuximab + Cis + Gem | 3 | 3 | |
| other | RASH | Skin and subcutaneous tissue disorders | Safety run-in Part: Cil (2000 mg) + Cetuximab + Cis + Vin | 3 | 3 | |
| other | RASH | Skin and subcutaneous tissue disorders | Randomized Part: Cil (Once Weekly) + Cetuximab + Chemotherapy | 35 | 85 | |
| other | RASH | Skin and subcutaneous tissue disorders | Randomized Part: Cil (Twice Weekly) + Cetuximab + Chemotherapy | 17 | 50 | |
| other | RASH | Skin and subcutaneous tissue disorders | Randomized Part: Cetuximab + Chemotherapy | 29 | 80 | |
| other | ACNE | Skin and subcutaneous tissue disorders | Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Gem | 0 | 3 | |
| other | ACNE | Skin and subcutaneous tissue disorders | Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Vin | 0 | 3 | |
| other | ACNE | Skin and subcutaneous tissue disorders | Safety run-in Part: Cil (2000 mg) + Cetuximab + Cis + Gem | 0 | 3 | |
| other | ACNE | Skin and subcutaneous tissue disorders | Safety run-in Part: Cil (2000 mg) + Cetuximab + Cis + Vin | 0 | 3 | |
| other | ACNE | Skin and subcutaneous tissue disorders | Randomized Part: Cil (Once Weekly) + Cetuximab + Chemotherapy | 19 | 85 | |
| other | ACNE | Skin and subcutaneous tissue disorders | Randomized Part: Cil (Twice Weekly) + Cetuximab + Chemotherapy | 11 | 50 | |
| other | ACNE | Skin and subcutaneous tissue disorders | Randomized Part: Cetuximab + Chemotherapy | 17 | 80 | |
| other | DERMATITIS ACNEIFORM | Skin and subcutaneous tissue disorders | Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Gem | 0 | 3 | |
| other | DERMATITIS ACNEIFORM | Skin and subcutaneous tissue disorders | Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Vin | 0 | 3 | |
| other | DERMATITIS ACNEIFORM | Skin and subcutaneous tissue disorders | Safety run-in Part: Cil (2000 mg) + Cetuximab + Cis + Gem | 0 | 3 | |
| other | DERMATITIS ACNEIFORM | Skin and subcutaneous tissue disorders | Safety run-in Part: Cil (2000 mg) + Cetuximab + Cis + Vin | 0 | 3 | |
| other | DERMATITIS ACNEIFORM | Skin and subcutaneous tissue disorders | Randomized Part: Cil (Once Weekly) + Cetuximab + Chemotherapy | 17 | 85 | |
| other | DERMATITIS ACNEIFORM | Skin and subcutaneous tissue disorders | Randomized Part: Cil (Twice Weekly) + Cetuximab + Chemotherapy | 7 | 50 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00842712/events